

What: Date & Time: Location: **Operations Committee Meeting**

May 7, 2020, 12:30-1:30 p.m. PT ZOOM Webinar/Teleconference *To participate, please email <u>info@wavaccine.org</u> and the webinar/teleconference information will be sent to you.*

Notice: Meeting may be recorded for the benefit of the secretary. The WVA intends to delete the recording after the minutes of the meeting are approved.

Approx. Time	*Page	Topic/[Anticipated Action]	Presented by:
1:30-1:35 p.m.		 Introductions & Purpose of Meeting Notice of Recording 	J. Zell
1:35-1:40p.m.	2-4	 Calendar Consent Items (VOTE) Operations Committee Minutes (December 5, 2019) 	J. Zell
1:40-2:00 p.m.	5-32	 2020-21 Vaccine Assessment Grid a. 2020-21 Vaccine Assessment Grid (VOTE) 	P. Miller/J. Zell
2:00-2:25 p.m.	33-43	 4. Operations Update a. Administrator Change b. 2020 Goals c. Provider and Payer Guide d. Refunds/Denials 	J. Zell
2:25-2:30 p.m.		5. Other Matters from Committee Members	Any
2:30 p.m.		6. Closing	J. Zell



May 7, 2020 WVA Meeting of the Operations Committee Proposed Form of Votes

The following are suggested forms of votes only. They are intended to be an aid to facilitate work by individual directors and committee members.

Items under Agenda Section 2:

VOTED:To approve the meeting minutes of the December 5, 2019 Operations
Committee meeting.

[To approve the meeting minutes of the December 5, 2019 Operations Committee meeting with the changes suggested at the meeting.]

Items under Agenda Section 3:

VOTED: To adopt the July 1, 2020 Assessment Grid.

[To adopt the July 1, 2020 Assessment Grid in accordance with the changes suggested at the meeting.]



Washington Vaccine Association **Operations Committee Meeting** December 5, 2019; 1:00-1:30 p.m. PDT

I. Attendance. Participating in all or part of the meeting by telephone were the following individuals:

Members SheAnne Allen, Department of Health Tracey Cardillo, Cigna Nicole Carroll, United Healthcare Steve Lam, PharmD, Regence

Helms & Company, Inc. Patrick Miller, Principal

KidsVax[®] Terry Mills, Executive Assistant

WVA Julia G. Zell, Esq., Executive Director, Chair

6 П. Minutes

7

1

2

3

4 5

8 Welcome and Introductions

9 At 1:00 p.m., Chairperson Julia Zell called the meeting to order. The purpose of the meeting is to introduce everyone 10 to Helms & Company, who will be the new administrative services provider to WVA beginning January 1, 2020.

11

12 **Financial Update**

Ms. Zell indicated that like the old process, WVA will provide a draft assessment grid. It is anticipated that WVA 13 14 will be able to absorb inflation costs in the ongoing year. WVA is fully reserved partly due to the TRICARE settlement 15 in which TRICARE paid their arrears owed to WVA. Given WVA's liquidity, Ms. Zell believes the assessment grid 16 can be taken down again. WVA is attempting to hold the grid steady as payers have articulated in the past, they would prefer fewer adjustments to the assessment grid versus the up and down, allowing for better predictability. Ms. Zell 17 18 mentioned that if anyone is interested in additional information, WVA's Finance Committee makes the decisions 19 concerning what WVA's reserve goals are and how to adjust them on a periodic basis. Those meetings are posted on

20 WVA's website at www.wavaccine.org. All 2020 meetings have been posted on the website.

22 **Operations Updates**

Ms. Zell provided a brief update regarding the transition from KidsVax ("KV") to Helms & Company ("Helms") 23 24 beginning January 1, 2020. After an exhaustive search, Helms was selected to handle WVA's back office work, 25 including projections, customer service, and other tasks not handled by Ms. Zell specifically. She explained that there 26 will be some changes on the provider side, whereas Helms will have a full-time person that will be handling the 27 inquiries coming in day to day. WVA also recently had its website updated, so different content will continue to be 28 added to that as well. The News and Notices will remain in the same place so that payers will continue to receive a 29 reminder of the draft assessment grid. Helms has a lot of experience with vaccine associations and have collectively,

- 30 years and years of payer and provider experience. Ms. Zell is excited to have them on the team.
- 31 32

33

34

35

36

37

38

21

Mr. Miller expressed Helm's excitement about working with WVA as well. From a payer's perspective, Mr. Miller explained that initially things will look the same in terms of not changing phone numbers, email addresses, the lockbox, etc. At a recent visit with WVA's Board, Mr. Miller explained that while it looks the same today, Helms is actively working on some items on the back end that will be beneficial to the payers, WVA, and the Department of Health ("DOH"). Technology has been implemented that will take all the documents that go to the lockbox, i.e., EOBs, checks, and correspondence related to the DBA claim process and image all of those and then extract off that approximately 25 data points. This process with give the customer service people more of a real time view of what

39 has been sent there, but it also provides a fair amount of analytic capacity to look at the data. Mr. Miller has had a 2020, Helms would like to move into looking at how WVA can move away from the paper-based EOB process and move more to an automated 835 process. Helms believes this process will be a great value to the payers in terms of being able to move from paper to electronic. It will reduce several lags that exist through the lockbox. There are also a number of upstream activities that Helms is looking at. One of the things that the analytic platform provides is the ability to take a look at the pricing grid in terms of what is on the grid versus what is actually being processed on the charge and payment side. Helms is hoping to work more proactively with some of the providers that might not be up to date on the grid and potentially some of the smaller payers that are not necessarily up to speed.

8

9 Mr. Miller offered to meet with anyone individually or as a group going forward and would like to develop a strong 10 collaboration between Helms & Company and the payer community, as they have been developing with the DOH.

11

Ms. Zell reported that one of the things that attracted the Board to Helms was the fact that they had a proposal that included taking a lot of the paper EOBs and payments and putting them on an automated platform. This plan should give WVA a lot more feedback and close some of the time lag that currently exists as far as its revenue cycle and provide a better idea of what those estimated assessment levels should be. In the future, it is anticipated that WVA will be able to give reports on quantifying leakage and hopefully plugging any of the holes so that WVA can assure that every payer is paying equitably and that providers are doing exactly what they should be doing when they're

assessing. Some of that is being done now, but it is not the same when it is being done manually versus having that

19 ongoing data.

2021 Ms. Zell also indicated that some of the projections will be changing and that is because of this additional information.

Due to WVA's liquidity, it will still be burning down some of its reserves slowly, but because of the accuracy going forward, and a little more robust process as far as the assessment grid setting, there should be even more accurate projections in future years. Helms will be working closely with the DOH to pick the monthly purchases and over time

25 can start to track purchases versus utilization.

26

27 **DOH Updates**

28 Ms. Allen briefly reported that DOH will be working with Ms. Zell and Helms to make sure that DOH is providing 29 what they find helpful and then assess the process moving forward. DOH is also working on the individual provider 30 profile update project. There was conversation about its provider punch list being updated next summer. However, 31 to be proactive, they started on the project about a month ago and are hoping to have that wrapped up and have all 32 provider profiles input by the end of the year. This is typically done every three years, but it has been done a little 33 earlier this year because of the transition and making sure everything is accurate. Ms. Zell explained that a practice 34 profile is the actual determination as far as what WVA is accountable for to the DOH for the purchase of vaccines. It 35 is a very important number and WVA appreciates the DOH for putting in that work early when they are not required 36 to by the CDC or the State.

30

Ms. Zell reported that notification letters regarding the transition will be going out. Going forward everything will be
branded under WVA so there is no confusion to payers and providers to assist in effectuating a smooth transition. Ms.
Zell reminded everyone to look for the News and Notices coming out and noted WVA will go through the normal
assessment cycle pending whatever the CDC pediatric contract is April 1, 2020.

42

43 Other Matters from Committee Members

44 There were no other matters to come before the Committee.

- 45
- 46 Closing
- 47 There being no further business, the meeting was adjourned at approximately 1:16 p.m. PST.



2020-21 Vaccine Assessment Grid

Presented to the Washington Vaccine Association Operations Committee

May 7, 2020

Leslie Walker, CPA Patrick Miller, MPH Tony Mendez, MBA

Confidential and Proprietary – For Internal WVA Purposes / Use Only

Packet Page 5

Presentation Overview


- The Vision
- Historical Charts
- Cash Flow Model
- Administrative Budget
- Vaccine Pricing Grid
- Discussion

2




The Vision

- 1. There is a "nested" relationship between the administrative budget, the cash flow model, and the vaccine pricing grid that was not taken into account in prior years
- 2. Goals of the FY2021 vaccine pricing grid process include:
 - 1. Providing grid stability across years to minimize year-to-year fluctuation
 - 2. Reducing cash on hand to a Board-approved level
 - 3. Allowing for reasonable reserves
- 3. This requires a partnership between the WVA, the payers, and the WA DOH



Confidential and Proprietary – For Internal WVA Purposes / Use Only



Historical Charts

Confidential and Proprietary – For Internal WVA Purposes / Use Only HELMS COMPANY




Purpose

- Charts are intended to provide the Board with a set of historical key indicators
- These indicators are reference points for the upcoming presentation sections
- These indicators will be added to future financial reporting packages



Total Inflows, Outflows, and Net Cash Reserves as of June 30 (\$M) - FY2016-20




<u>Note</u>: Since FY2017, the organization has been collecting revenues in excess of DOH vaccine funding requirements which has led to a build up of cash reserves.

Confidential and Proprietary – For Internal WVA Purposes / Use Only



Cash and Cash Equivalents and Investments (\$M) - FY2016-20




<u>Note</u>: Projected cash reserves at the end of FY2020 is \$60M, the majority of which is held in the Morgan Stanley investment portfolio.

Confidential and Proprietary – For Internal WVA Purposes / Use Only



Historical and Projected End of FY Cash Balance - FY2016-23




<u>Note</u>: This shows the historical and projected cash reserves balance at the end of each FY. FY2021-2023 projections will depend on the final cash model scenario the Board chooses.

Confidential and Proprietary – For Internal WVA Purposes / Use Only

MPANY



Weighted Average Grid Price Vs. Weighted Average Private Sector Price - FY2017-21



<u>Note</u>: The CDC private sector weighted average grid price is greater than the WVA weighted average grid price.

Confidential and Proprietary – For Internal WVA Purposes / Use Only



Administrative Budget

Confidential and Proprietary – For Internal WVA Purposes / Use Only HELMS COMPANY



Administrative Budget Categories


- Direct Processing Costs
 - Helms, OrbogGraph, Clearinghouses, Lockbox, CollaborateMD
- ED Costs and Related Support Fees
 - Salary, Payroll Taxes, Payroll Processing, Travel, Technology Support
- Provider and Payer Education and Outreach
 - Education Materials, Postage, Website, Technical Consultant, Conferences, Advertising, Hospitality, Subcontracted Educator
- Administrative Costs
 - Legal, Audit, Investment Management Fees, Registered Agent Fee, Rent, Board Meetings, Insurance
- Other Discretionary Expenditures
 - Administrator Conversion, ED and Contractor Bonus, Denied Claims Recovery, Direct Healthcare Practices Operations

Administrative Budget Summary

	Histo	orical		Forecast	
WVA Budget Summary	Budgeted	Projected Actual	Budgeted Total	Budgeted Total	Budgeted Total
	FY 2020	FY 2020	FY 2021	FY 2022	FY 2023
Direct Processing Costs					
	503,867	688,543	1,064,981	1,049,851	1,046,805
Executive Director Costs and Related Support Fees					
	308,492	345,598	345,252	350,981	356,852
Provider and Payer Education and Outreach ★					
	64,959	61,125	189,000	154,000	154,000
Administrative Costs					
	239,410	306,040	262,400	214,690	196,019
Other Discretionary Expenditures					
	100,000	616,000	166,000	166,000	166,000
Total Budget	1,216,728	2,017,305	2,027,633	1,935,521	1,919,676
Other Uncategorized Expenses	46,807				
Total PY Budget	1,263,535				

<u>Note</u>: The FY2021 administrative budget will be reviewed by the Finance Committee in May 2020. ★=additional investment.

Confidential and Proprietary – For Internal WVA Purposes / Use Only



Cash Flow Model


Confidential and Proprietary – For Internal WVA Purposes / Use Only HELMS COMPANY

A New Process - Flexibility and Control for the Board



Confidential and Proprietary – For Internal WVA Purposes / Use Only HELMS COMPANY

Cash Flow Model Scenarios



Note: The "At Cost" scenario in green is the recommended scenario.

Confidential and Proprietary – For Internal WVA Purposes / Use Only



M/V/A Einancial Medal	Histo	rical	Projected	Forecast Period - At		Cost
WVA Financial Model	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023
Assumptions						
Assessment Grid Markup				1	1	
Indirect				1.4%	1.4%	1.49
DOH Cost Recovery Fee				3.0%	2.6%	2.69
Vaccine Wastage		.djustment Va	riphlos	3.0%	2.0%	2.09
Denials		ujustnent va	Tiables	10.5%	8.0%	6.09
Denial Recoveries				3.5%	3.0%	2.09
% of Investments on Ending Cash Balance				90%	90%	909
nflows/Outflows						
Assessment Revenue	84,137,375	87,262,137	81,113,594	74,499,160	77,083,349	79,395,849
/accine Replenishment	65,835,583	65,491,991	63,139,509	74,499,160	77,083,349	79,395,849
nvestment Income	-	51,903	1,158,897	-	-	
RICARE Expense Offset	-	-	191,858	-	-	-
Gross Revenue	18,301,792	21,822,049	19,324,840	-	-	-
Administrative Cost				(1 042 099)	(1 070 167)	/1 111 5/2
ndirect DOH Cost Recovery Fee	-	-	-	(1,042,988) (2,224,075)	(1,079,167) (2,004,167)	(1,111,542 (2,064,292
Vaccine Wastage	-	-	-	(2,234,975) (2,234,975)	(2,004,167) (1,541,667)	(2,084,292)
Denials	-	-	-	(2,234,973) (7,822,412)	(6,166,668)	(4,763,75)
Denial Recoveries		-	_	2,607,471	2,312,500	1,587,91
Administrative Budget	- (1,189,899)	- (1,821,862)	- (1,310,555)	(2,027,633)	(1,935,521)	(1,919,67)
Total Administrative Cost	(1,189,899)	(1,821,862)	(1,310,555)	(12,755,512)	(10,414,689)	(9,859,262
Revenue in Excess of Expenditures	17,111,893	20,000,187	18,014,285	(12,755,512)	(10,414,689)	(9,859,26
Effect on Cash Reserves						
	0 500 050	24 420 004	F0 477 074	CO 404 405	47 720 600	27 222 000
Cash Reserves Beginning Balance	9,582,053	34,130,094 16,347,877	50,477,971	60,494,195	47,738,683	37,323,993
Cash Generated/ (Used)	24,538,923		10,016,224	(12,755,512)	(10,414,689)	(9,859,262
Cash Reserves Ending Balance	34,130,094	50,477,971	60,494,195	47,738,683	37,323,993	27,464,732
nvestments	9,118	45,555,976	54,444,775	42,964,814	33,591,594	24,718,259
Cash and Cash Equivalents	34,120,976	4,921,995	6,049,419	4,773,868	3,732,399	2,746,473

Confidential and Proprietary – For Internal WVA Purposes / Use Only

HELMS

COMPANY



Cash Flow Model "Dials" and "At Cost" Scenario Assumptions Summary

Adjustment Variable	Assumptions for "At Cost" Scenario				
	FY2021	FY2022	FY2023		
Assessment Grid Markup	1	1	1		
Indirect	1.4%	1.4%	1.4%		
DOH Cost Recovery Fee	3.0%	2.6%	2.6%		
Vaccine Wastage	3.0%	2.0%	2.0%		
Denials	10.5%	8.0%	6.0%		
Denial Recoveries	3.5%	3.0%	2.0%		
Percentage of Investments on Ending Cash Balance	90%	90%	90%		
Cash "Burn Down" Amount	\$12.8M	\$10.4M	\$9.9M		
Administrative Budget	\$2.0M	\$1.9M	\$1.9M		
CDC Price Increase	3.0%	3.0%	3.0%		

Confidential and Proprietary – For Internal WVA Purposes / Use Only



Contingency Funds Discussion

- Reasons for contingency funds:
 - COVID-19 administrative resources needed
 - COVID-19 vaccine developed
 - Vaxelis 2021 will be released
 - Periodic changes in VFC fund split
 - Current capacity to fund



Vaccine Pricing Grid

Confidential and Proprietary – For Internal WVA Purposes / Use Only HELMS COMPANY



Vaccine Pricing Grid

Washington Vaccine Association Assessment Grid FOR ALL CLAIMS WITH A DATE OF SERVICE ON OR AFTER JULY 1, 2020.

Please note that this WVA Assessment Grid, effective July 1, 2020, replaces the grid last updated on July 1, 2019. The grid lists vaccines and their corresponding CPT codes that are part of the dosage-based assessment (DBA) process for providers, health insurance carriers, and third party administrators. There are other childhood vaccines (and corresponding CPT codes) that are not included in the DBA process and, therefore, no assessment is needed. The availability of specific vaccine brands are determined by the manufacturer and not all brands of flu vaccine are offered through the Childhood Vaccine Program (CVP). The green column is the assessment amount per dose as of 7/1/2020.

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2019	CDC Private Sector Cost/Dose 4/1/20	WVA Assessment Amount per dose as of 7/1/2020	Percent change 7/1/2019 to 7/1/2020
90620	58160-0976-20 (10 pack – 1 dose syringe) 58160-0976-06 (1 pack – 1 dose syringe)	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use	Bexsero®	\$151.07	\$170.75	\$120.84	-20.0%
90621		Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use	Trumenbo	heel	\$149.89	\$115.17	-5.2%
90633		Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use Hepatitis A vaccine (HepA), pediatric/adolescent d intramuscular use	preads	\$22.88	\$32.89	\$20.72	-9.4%
	00006-4095-02 (10 pack – 1 dose syringe)	and E. Refer Le	Vaqta®		\$33.30		
90647	00006-4897-00 (10 pack – 1 dose vial)	Hac s of the second sec	PedvaxHIB®	\$14.73	\$26.23	\$13.54	-8.1%
00040	49281-0545-03 (5 pack – 1 dose vial)	Ha SPACE type b vaccine (Hib), PRP-T conjugate, 4 dose	ActHIB®	\$10.55	\$17.14	A0 40	10.00/
90648	58160-0818-11 (10 pack – 1 dose vial)	sch intramuscular use			\$10.85	\$9.46	-10.3%
90651	00006-4119-03	Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use	Gardasil®9	\$198.64	\$227.93	\$189.08	-4.8%
90670	00005-1971-02 (10 pack – 1 dose syringe)	Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use	Prevnar 13 TM	\$152.78	\$202.00	\$144.84	-5.2%

Confidential and Proprietary – For Internal WVA Purposes / Use Only



Contact: Patrick B. Miller, MPH 603.225.6633 | office 603.415.8010 | direct pmiller@helmsco.com





MEMORANDUM

TO:	Julia Zell, Executive Director & WVA Board of Directors
FROM:	Leslie Walker, CPA (Mason+Rich PA), Patrick Miller, MPH (Helms), and Tony Mendez, MBA (Helms)
SUBJECT:	2020-21 WVA Vaccine Assessment Grid Recommendation
DATE:	May 1, 2020


Introduction

The purpose of this memorandum is to provide the Washington Vaccine Association's Board of Directors and Operations Committee with Helms & Company's recommendations for the 2020-21 Vaccine Assessment Grid ("Grid") and a description of the underlying assumptions. The development of the 2020-21 Grid included several changes from prior years. The administrative budget, cash flow projections based upon Board targets, and the Grid are now integrated into a unified model. The purpose of which is to allow the Board of Directors flexibility in setting a series of overall adjustment factors to produce different scenarios over a three-year time horizon. These scenarios drive the required burn down of cash and subsequently the amount of money the Grid needs to "raise" to meet the organization's obligations.

FY2020 Grid Summary

In FY2020, a two percent reduction adjustment was made in the Grid prices in order to "reduce cash by between \$6.5 million and \$7M within one year" and to "anticipate balances on operating cash of \$5.7 million and \$35.6


million in investment accounts at June 30, 2020."¹ As shown in Figure 1, what happened instead was that while the two percent reduction adjustment had some reduction on cash, cash still *grew* from \$50,477,971 on July 1, 2019 to \$58,400,151 on December 31, 2019 and to \$59,489,301 on March 31, 2020 – increases of \$7,922,181 and \$9,011,059, respectively during these two time periods. The reason for this growth in cash is that the FY2020 Grid was priced nearly 12% above the vaccine remittances



to the State of Washington. The two percent reduction adjustment was inadequate to achieve the desired goal.

Setting FY2021-FY2023 Cash Targets

The Finance Committee has set a goal of reducing cash and setting targets for reduction. The model created for the upcoming FY assumes cash decreasing over the next three years with end of year cash balances of \$47.7M, \$37.3M, and \$27.5M at the end of each of the next three fiscal years, respectively (Figure 2). For each of the three years, the model targets reductions of \$12.8M, \$10.4M, and \$9.9M over the next three fiscal years, respectively. This allows the Grid price to remain



fairly constant over a three-year period while bringing cash reserves down.

¹ Memorandum dated April 10, 2019, from Peter Smith, KidsVax, to the WVA Board of Directors



FY2021-2023 Grid Assumptions

The following assumptions were made in the new financial model with respect to setting the 2020-21 Grid prices:

- 1. The Department of Health's (DOH) November 2019 <u>projections of vaccine utilization</u> formed the underpinnings of the initial model for the April 23, 2020 Board meeting. The DOH provided an update projection on April 27, 2020, and revised downward the total doses from 1,238,255 to 1,210,000.
- 2. On April 1, 2020, the Centers for Disease Control ("CDC") <u>updated its Vaccine Price List²</u> for the CDC cost per dose and the private sector cost per dose. The cost per dose increased 3% over the prior year. The April 1, 2020 CDC prices were used for the development of the 2020-21 Grid.
- 3. The <u>Assessment Grid Markup</u> will be zero, meaning that the proposed Grid price will effectively equal the CDC contract price. The final Grid price was calculated as the weighted average CDC contract price for vaccines paid for between July 1, 2020 and April 30, 2021 on the April 1, 2020 CDC price list and the contract price for vaccines paid for between May 1, 2021 and June 30, 2021 on the April 1, 2020 CDC price list.
- 4. The <u>Department of Health's Indirect Rate</u> will be held steady at 1.4% for the next three fiscal years.
- 5. The <u>Department of Health's Cost Recovery Fee</u> will be 3% for the upcoming fiscal year and 2.6% for the following two fiscal years. The estimated 0.4% increase in the upcoming fiscal year is being reserved for additional DOH Covid-19 and provider education costs.
- 6. Based upon provider remittance data, the current <u>DBA denial rate</u> is currently in excess of 10.5%, versus the 3% number used in prior modeling. We expect this to drop to 8% and 6% in the latter two fiscal years based upon planned denial recovery activities.
- 7. The <u>denial recovery rate</u> is expected to be 3.5% in FY2021 and 3% and 2% in the latter two fiscal years.
- 8. The percentage of assets held in investments is estimated to be 90%.

Analysis of Changes

The attached 2020-21 Grid update has been reviewed with the Department of Health. The total projected assessments in FY 2021 are \$74,499,160. The 2020-21 Grid prices are significantly lower than the CDC private sector prices, resulting in a projected \$19,163,247 difference for the year. The prior year's Grid prices are shown in grey and the FY2021 Grid prices are in green to make it easier to read. Overall, the Grid prices dropped 13.7% between the 2019-20 and the 2020-21 Grid.

#

² <u>https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html</u>



Washington Vaccine Association Assessment Grid FOR ALL CLAIMS WITH A DATE OF SERVICE ON OR AFTER JULY 1, 2020.

Please note that this WVA Assessment Grid, effective July 1, 2020, replaces the grid last updated on July 1, 2019. The grid lists vaccines and their corresponding CPT codes that are part of the dosage-based assessment (DBA) process for providers, health insurance carriers, and third party administrators. There are other childhood vaccines (and corresponding CPT codes) that are not included in the DBA process and, therefore, no assessment is needed. The availability of specific vaccine brands are determined by the manufacturer and not all brands of flu vaccine are offered through the Childhood Vaccine Program (CVP). The green column is the assessment amount per dose as of July 1, 2020.

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2019	CDC Private Sector Cost/Dose 4/1/20	WVA Assessment Amount per dose as of 7/1/2020	Percent change 7/1/2019 to 7/1/2020
90620	58160-0976-20 (10 pack – 1 dose syringe) 58160-0976-06	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use	Bexsero®	\$151.07	\$170.75	\$120.84	-20.0%
90621	(1 pack – 1 dose syringe) 00005-0100-10 (10 pack – 1 dose syringe)	Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use	Trumenba®	\$121.49	\$149.89	\$115.17	-5.2%
90633	58160-0825-11 (10 pack – 1 dose vial) 58160-0825-52 (10 pack – 1 dose syringe)	Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for	Havrix®	\$22.88	\$32.89	\$20.72	-9.4%
90033	00006-4095-02 (10 pack – 1 dose syringe)	intramuscular use		φ22.00	\$33.30	φ20.72	-9.4 %
90647	00006-4897-00 (10 pack – 1 dose vial)	Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use	PedvaxHIB®	\$14.73	\$26.23	\$13.54	-8.1%
MUNAA	49281-0545-03 (5 pack – 1 dose vial) 58160-0818-11 (10 pack – 1 dose vial)	Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use	ActHIB® Hiberix®	\$10.55	\$17.14 \$10.85	\$9.46	-10.3%
90651	00006-4119-03 (10 pack – 1 dose vial) 00006-4121-02 (10 pack – 1 dose syringe)	Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use	Gardasil®9	\$198.64	\$227.93	\$189.08	-4.8%
90670	00005-1971-02 (10 pack – 1 dose syringe)	Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use	Prevnar 13 TM	\$152.78	\$202.00	\$144.84	-5.2%
	00006-4047-41 (10 pack – 1 dose tube) 00006-4047-20 (25 pack – 1 dose tube)	Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use	RotaTeq®	\$78.60	\$84.53	\$72.04	-8.3%

CPT Code	NDC Code / Packaging	CPT Code Description			CDC Private Sector Cost/Dose 4/1/20	WVA Assessment Amount per dose as of 7/1/2020	Percent change 7/1/2019 to 7/1/2020
90681	58160-0854-52 (10 pack – 1 dose vial)	Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use	Rotarix®	\$105.59	\$120.95	\$97.88	-7.3%
90696	58160-0812-11 (10 pack – 1 dose vial) 58160-0812-52 (10 pack – 1 dose syringe)	Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use	Kinrix®	\$46.06	\$52.14	\$41.93	-9.0%
	49281-0562-10 (10 pack – 1 dose vial)	,	Quadracel™		\$54.63		
	49281-0510-05 (5 pack – 1 dose vial)	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use	Pentacel®	\$66.26	\$99.83	\$61.94	-6.5%
	49281-0286-10 (10 pack – 1 dose vial)		Daptacel®		\$31.70		
90700	58160-0810-11 (10 pack – 1 dose vial) 58160-0810-52	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than seven years, for intramuscular use	Infanrix®	\$20.82	\$24.71	\$18.63	-10.5%
00702	(10 pack – 1 dose syringe) 49281-0225-10 (10 pack – 1 dose vial)	Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use	DT (pediatric)	\$59.59	n/a	\$59.59	0.0%
00707	00006-4681-00 (10 pack – 1 dose vial)	Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use	M-M-R®II	\$23.66	\$78.68	\$21.77	-8.0%
90710	00006-4171-00 (10 pack – 1 dose vial)	Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use	ProQuad®	\$146.52	\$224.94	\$138.67	-5.4%
0/1/1/2	49281-0860-10 (10 dose vial)	Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use	IPOL®	\$15.11	\$35.17	\$13.90	-8.0%
90714	49281-0215-15 (10 pack – 1 dose syringe) 49281-0215-10 (10 pack – 1 dose vial)	Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use	Tenivac®	\$22.98	\$34.80	\$16.42	-28.6%
	13533-0131-01 (10 pack – 1 dose vial)	Tetanus and diphtheria toxoids (Td) adsorbed when administered to individuals 7 years or older, for intramuscular use	TDVAX™		\$25.88		

DRAFT

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2019	CDC Private Sector Cost/Dose 4/1/20	WVA Assessment Amount per dose as of 7/1/2020	Percent change 7/1/2019 to 7/1/2020
90715	58160-0842-11 (10 pack – 1 dose vial) 58160-0842-52 (10 pack – 1 dose syringe)	Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when	Boostrix®	¢25.05	\$41.19	¢20.70	-9.0%
90715	49281-0400-10 (10 pack – 1 dose vial) 49281-0400-20 (5 pack – 1 dose syringe)	administered to individuals 7 years or older, for intramuscular use	Adacel®	\$35.95 \$46.80		\$32.73	-9.0%
90716	00006-4827-00 (10 pack – 1 dose vial)	Varicella virus vaccine (VAR), live, for subcutaneous use	Varivax®	\$116.07	\$135.73	\$110.28	-5.0%
	58160-0811-52 (10 pack – 1 dose syringe)	Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use	Pediarix®	\$65.85	\$79.15	\$60.96	-7.4%
90732	00006-4837-03 (10 pack – 1 dose syringe) 00006-4943-00 (10 pack – 1 dose vial)	Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use	Pneumovax®23	\$62.78	\$105.19	\$59.78	-4.8%
90734	49281-0589-05 (5 pack – 1 dose vial)	Meningococcal conjugate vaccine, serogroups A, C, Y and W-135,	Menactra®	\$105.76	\$128.38	\$96.15	-9.1%
90734	58160-0955-09 (5 pack – 1 dose vial)	quadrivalent (MCV4 or MenACWY), for intramuscular use	Menveo®	\$105.70	\$130.75	φ 9 0.15	-9.170
	00006-4981-00 (10 pack – 1 dose vial)		Recombivax HB®		\$23.95		
90744	00006-4093-02 (10 pack – 1 dose syringe)	Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use	Recombivax HB®	\$17.37	\$23.95	\$12.54	-27.8%
	58160-0820-52 (10 pack – 1 dose syringe)		Engerix B®		\$23.72		
2020	-2021 Pediatric Influenza V	accine Assessments					
90686	19515-0816-52 (10 pack – 1 dose syringe)	mL dosage, for intramuscular use	FluLaval® Quadrivalent	\$15.13	\$17.30	\$13.50	-10.8%
30000	49281-0420-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent SYR	φ15.15	\$18.14	\$13.50	-10.8%
90688	49281-0633-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent MDV	\$15.34	\$16.94	\$13.55	-11.7%
90672	66019-0307-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist® Quadrivalent	\$21.05	\$23.70	\$18.88	-10.3%
90674	70461-0320-03 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use to modify the Assessment Grid in effect at any time with Beerd appr		\$17.42	\$32.47	\$16.02	-8.0%




		DISCONTINUED PEDIATRIC INFLUENZA NDC CODE	<u>S</u> AS OF JUNE 30,	2020			
CPT Code	NDC Code / Packaging	CPT Code Description		Tra	dename		
90686	19515-0906-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent				
90686	49281-0419-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone [®] Quadrivale	ent SYR			
90672	66019-0306-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist [®] Quadrivaler	nt			
90688	49281-0631-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone [®] Quadrivale	ent MDV			
90674	70461-0319-03 (10 pack - 1 dose syringe)	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax [®] Quadriva	lent			
		DISCONTINUED <u>CPT CODES</u> FROM JULY 1, 2019	ASSESSMENT GR	ID			
CPT Code	NDC Code / Packaging	July 1, 2019 Grid CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2018	CDC Private Sector Cost/Dose 4/1/19	WVA Assessment Amount per dose as of 7/1/2019	Percent change 7/1/2018 to 7/1/2019
90636	58160-0815-52 (10 pack – 1 dose syringe)	Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use. (Age 18 only for CVP)	Twinrix®	\$76.58	\$104.00	\$67.29	-12.1%
	•	DISCONTINUED <u>CPT CODES</u> FROM JULY 1, 2018	ASSESSMENT GR	ID			
CPT Code	NDC Code / Packaging	July 1, 2018 Grid CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2018	CDC Private Sector Cost/Dose 4/1/19	WVA Assessment Amount per dose as of 7/1/2019	Percent change 7/1/2018 to 7/1/2019
90685	49281-0518-25 (10 pack - 1 dose syringe)	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6 - 35 months of age, for intramuscular use (Code Price is per 0.25 mL dose)	Fluzone Pediatric Preservative Free (PF)	\$23.16	\$19.26	\$18.53	-20.0%
		DISCONTINUED CPT CODES FROM JULY 1, 2017		ID			
CPT Code	NDC Code	July 1, 2017 Grid CPT Code Description	Trade Name(s)	WVA Assessment Amount per dose as of 7/1/2016	CDC Market Survey	WVA Assessment Amount per dose as of 7/1/2017	Percent change 7/1/2016 to 7/1/2017
90644	58160-0801-11	Meningococcal conjugate vaccine, serogroups C & Y and Hemophilus influenza B vaccine (Hb-MenCY), 4 dose schedule, when administered to high risk children 2 - 15 months of age, for intramuscular use	MenHibrix	\$14.72	\$24.71	\$14.72	0.0%
Page 4		DRAFT			Pac	ket Page ຟິລາໃຜ	ated 5/1/2020

CPT Code	NDC Code	July 1, 2017 Grid CPT Code Description	Trade Name(s)	Amount per	CDC Market Survey	WVA Assessment Amount per dose as of 7/1/2017	Percent change 7/1/2016 to 7/1/2017
90649		Human Papilloma Virus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent), 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	Gardasil	n/a	n/a	n/a	n/a
90650		Human Papilloma virus (HPV) vaccine, types 16, 18, bivalent, 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	Cervarix	n/a	n/a	n/a	n/a
90743		Hepatitis B vaccine, adolescent dosage (2-dose schedule), for intramuscular use (Code price is per dose) (Recombivax HB 10mcg = one dose)	Recombivax HB	\$17.19	\$23.20	\$17.19	0.0%
90685	49281-0517-25	administered to children 6 - 35 months of age, for intramuscular use (Code Price is per 0.25 ml. dose)	Fluzone Pediatric Preservative Free (PF)	\$23.16	\$18.72	\$23.16	0.0%
90687	49281-0517-25	Influenza virus vaccine, quadrivalent, split virus, when administered to children 6-35 months of age, for intramuscular use	Fluzone	\$18.47	\$18.72	\$18.47	0.0%






"Swimlane" Process Diagram



(Revised) WVA Operations Process



Principles

1 Go Up Stream

- Close gaps in the open system
- Fix processes to improve data quality and reduce operational loads

(2) Transparency and Accountability

- Finances
- Operations


③ Partnerships

- Payers
- Providers
- Department of Health





Automation & Insights Game Plan



CONFIDENTIAL INTERNAL WORKING DOCUMENT



WVA Quarterly Goal Summary – Updated March 13, 2020

Workstream	Q1 CY2020 - PAST	Q2 CY2020 - CURRENT	Q3 CY2020 - FUTURE	Q4 CY2020 - FUTURE
Governance	 ✓ Board Chair Selection ✓ Finance Chair Selection ✓ MRM Review Scope ✓ Controls Recommendations 	 MRM Closure Controls Adoption Plan of Operation Review 	 Board Policies Review Board Committee Charters Review Governance Survey 	 Strategic Retreat Preparation
Automation and Data Build (accelerated schedule)	 ✓ ERA Intake Begins ✓ EFT Increases Begin ✓ QB File ✓ Payer DB ✓ KB->OG Lockbox Interface ✓ Jul-Oct 2019 KB->OG Lockbox Data Transfer 	 ERA Intake (Goal 50%) EFT Intake (goal 40%) ACH File from KeyBank to OrboGraph Update OrboGraph to QB File 	 ERA Intake (goal 70%) EFT Intake (goal 50%) 	 ERAs Intake (goal 80%) EFT Intake (goal 60%)
Analytics and Recoupment	 Initial Denial/Underpayment Analysis Define the Process (Legal) 	 DOH Data Use Agreement Patient Payments Strategy Developed Denial/Underpayment Strategy Developed Reclamation Tested with Two Payers 	 OrboGraph Database Export Strategy Options Developed Recoupment Status Updates 	 OrboGraph Database Export Strategy Options Decisioned Recoupment Status Updates
Communications - Payer	 ✓ Develop Strategy with DOH ✓ Analyze Payers' Provider Manuals for WVA Language 	 Denials Analysis Corrective Letters Payer Provider Manual Language Distribution 	 Denials Analysis Vaccine Grid Analysis Corrective Letters 	 Denials Analysis Vaccine Grid Analysis Corrective Letters
Communications - Provider	Redesign Provider Onboarding Materials	DOH NewsletterVaccine Grid Notice	Provider WebinarsDOH Newsletter	Provider WebinarsDOH Newsletter
Operations	 ✓ Call Center Go-Live; Provider and Payer Support (phone, email, fax) ✓ Payer Database Maintenance ✓ Analyze Payer Provider Manuals ✓ Policy and Procedure Manual 	 Develop Payer Provider Manual Model Language 2020-21 Vaccine Grid Modeling Payer Database Re-Design 	 2021 Vaccine Grid Changes in Effect Payer Database Live 	Revise Policies and Procedures
Finance	 ✓ Financial Processes Go-Live ✓ Cash Management Strategy Development ✓ Daily Activities Automation ✓ Policy and Procedure Manual 	 FY2021 Budgeting Implement Cash Management Strategy Document Payer Settlement Report Process 	 FY2021 Budget in Effect Review and Revise Cash Management Strategy Re-Design Payer Settlement Report Process 	 Payer Statutory Letters Created Review and Revise Cash Management Strategy Implement Payer Settlement Report Process



S UVP WASHINGTON VACCINE ASSOCIATION

PROVIDER & PAYER GUIDE







What We Do

PUBLIC/PRIVATE PARTNERSHIP


The Washington Vaccine Association (WVA) and the Washington State Department of Health (DOH) work together in a public/ private partnership to support Washington's universal Childhood Vaccine Program (CVP). The program provides publicly purchased vaccines that are recommended by the Advisory Committee on Immunization Practices (ACIP) for all children less than 19 years of age. Health plans and other payers reimburse the WVA for vaccines. The WVA collects these payments and transfers the funds to the State Department of Health where its the CVP purchases vaccines at federal contract rates and distributes vaccines to physicians, hospitals and other providers at no cost to providers or patients.

WVA MAKES IT POSSIBLE

- For all children to have easy access to critical vaccines.
- For physicians, clinics, and hospitals to receive state-supplied vaccines at no charge.
- For payers to participate in an efficient, cost-effective system to facilitate childhood vaccinations free to their members.

THE SYSTEM WORKS

- By having providers enroll in the Childhood Vaccine Program and using state-supplied vaccine material.
- By having providers submit the Dosage-Based Assessment (DBA) with their administrative claims submission. This critical step allows physicians, clinics, hospitals, other providers and patients to receive vaccine for all children at no cost.
- By ensuring that providers and payers do not bill patients, regardless of how the payer processes the submitted dosage-based assessment.



*There is no charge to patients.



File forms by mail **OR** electronically.

Providers will fill out the Health Insurance Claim Form (HCFA 1500) twice: once as the Administration Claim Form and once as the DBA Form.

STEP 1

Complete HCFA 1500 as the Administration Claim Form

Fill out HCFA 1500 Form for the administration of the vaccine. This claim should only include the administration code(s).

The modifier SL is used by managed Medicaid payers and traditional Medicaid. These are not plans that participate in the DBA process which is limited to commercial coverage.

H Billing Tip: Do NOT include vaccine codes and modifiers.

Dosage-Based Assessment Filing Basics

STEP 2

Complete HCFA 1500 as the DBA Form

* First: Go Get Your Grid!

The DBA Form includes administration claim information with changes:

- 1. **Box 19:** A good place for processing notes to payer if needed.
- 2. **Box 21:** Enter "Z 23" (this is the only diagnosis required).
- 3. Box 24d: Enter CPT code for the statesupplied vaccine given. (Do not include modifiers.)
- Box 24f: Enter WVA charge based on the current grid, found online at: <u>wavaccine.org/</u> <u>assessment-grid/</u>
- 5. Box 24j: Enter Provider's NPI number
- 6. Box 25: Enter WVA TIN (27-2251833)

- 7. Box 32a: Enter Provider NPI
- 8. **Box 33:** Enter Provider's Billing Office Phone Number. Enter WVA Address: Washington Vaccine Association, PO Box 94002, Seattle, WA 98124-9402
- 9. Box 33a: Enter the WVA NPI (1699092718)
- 10. Box 33b: Enter Billing Taxonomy Code: 251K00000X

STEP 3

Submit both versions via mail to payer

Mail the Administrative Claim Form and DBA Form to the payer (health plan, insurance company, or third-party administrator)– NOT to WVA.

★ Billing Tip: Do NOT submit to WVA.

STEP 1: ADMINISTRATION CLAIM FORM

	DMINISTRATION CLAIM WITH DBA FORM	Payer & Address according to patient's card (never WVA). Only commercial payers and patients under 19. Out of state patient plans are o.c. you may need to submit to local payer address.				
PROVED BY NATIONAL UNIFORM CLAIM COMM						
PPROVED BY INFORME ON POINT COMING COMING			PICA ITT			
MEDICARE MEDICAID TRICARE		1a. INSLAED S.D. NUMBER	(For Program in Item 1)			
(Medicare#) (Medicaid#) (D&DcD#)						
2. PATIENT'S NAME (Last Name, First Name, Middle	HISW) 3. PATIENT'S BIRTH DATE SEX	4. INSERTED'S NAME Nast Name, First	Name, Middle Initial)			
5. PATIENT'S ADDRESS (No., Street)	6. PATIENT RELATIONSHIP TO INSURED	7. INSURED'S ADORESS (No. Street)				
	Set Spouse Child Street					
DITY	STATE & RESERVED FOR NUCC USE	CITY	STATE			
Eill or	ut completely ac a	ucual da	EPHONE (Include Area Code)			
FIII O	ut completely as a	usual Cla				
	e, woode weap To its PATIENT'S CONSTRUCTION	T. NOUNED S POULT GROUP ON P				
. OTHER INSURED'S POLICY OR GROUP NUMBER	R a. EMPLOYMENT? (Current or Previous)	a. INSURED'S DATE OF BIRTH	SEX			
	YES NO		M F			
b. RESERVED FOR NUCC USE	b. AUTO ACCIDENTI PLACE (StaN)	b. OTHER CLAIM ID (Designated by N	UCC)			
RESERVED FOR NUCC USE	e. OTHER ACCIDENT?	C. NEUPANCE PLAN NAME OR PRO	STATE VALUE			
L PERSONNED FOR NUCL USE		12. INDUMANUE PLAN NAME OR PRO	annan ronditis			
5. INSURANCE PLAN NAME OR PROGRAM NAME	10d. CLAIM COOKIS (Designated by NUCC)	d. IS THERE ANOTHER HEALTH BEN	EFIT PLAN?			
		YES NO If yes	complete items 9, 9a, and 9d.			
 PATIENT'S OR AUTHORIZED PERSON'S 2 GNA to process this claim. I also request payment of pove below. 	FORE I authorize the release of any motion of other information necessary emment benefits entering myself or to the gamy also accepts assignment	payment of medical benefits to the u services described below.	ndersigned physician or supplier for			
SIGNED	DATE	SIGNED				
	DATE ONANCY (LMP) SE OTHER DATE OUL	SIGNED	RK IN CURRENT OCCUPATION			
14. DATE OF CURRENT ILLNESS, INJURY, or PREC	SNANCY (LVP) IS OTHER DATE MM DO YY	16. DATES PATIENT UNABLE TO WO MM DO YY FROM	то			
14 DATE OF CURRENT ILLNESS, INUXY, or RECO MM OU QUAL 17. NAME OF REFERRING PROVIDER OR OTHER I	DIANCY (LAY) 44. OTHER DATE (LM DD YY DIANCY (LAY) 44. OTHER DATE (LM DD YY DOUNCE 1728 175 147	16. DATES PATIENT UNABLE TO WO FROM 18. HOSPITALIZATION DATES RELAT MM FROM	TO ED TO CURRENT SERVICES MM DO TO			
14 DATE OF CURRENT ILLNESS, INJURY, OF NEED QUAL 17. NAME OF REFERRING PROVIDER OR OTHER 19. ADDITICINAL CLART INFORMATION CONCERNMENT A good Diace to reference OPT and A good Diace to reference OPT and	DANAC (CAM) 44. OTHER DATE (AM 0.0 YY BOUNCE 178 1 127 NOC 1 VACCINE USED	16. DATES PATIENT UNABLE TO WO FROM DI 18. HOSPITALIZATION DATES RELAT FROM 20. OUTSIDE LAB?	TO ED TO CURRENT SERVICES			
14 ONTE OF OURSELT ILLIESS. NUMER OF NOT	DIMANCY DUAS Lis strategicant List DD YY SOURCE 178	16. DATES PATIENT UNABLE TO WO FROM 1011 18. HOSPITALIZATION DATES RELAT MM 20. DUTSIDE LAB7 20. DUTSIDE LAB7 YES NO	TO ED TO CURRENT SERVICES MM DO TO			
M DATE OF OURPERT LUNESS, ALL YEAR HEALTHING ON THE OUR - OU	Other Control Fill Operation Fill Ope	16. DATES PATIENT UNABLE TO WO FROM DO TO	TO ED TO CURRENT SERVICES MM DO TO			
HA DATE OF DURINENT KLINESS, RALVER, O THEO OLAL. 17. INME OF REFERENCE PROVDER OR OTHER 19. ADDITIONAL CLARF SHORNDER OR OTHER A good picke to reference CPT and If needed for payer, and/or process 20. CRAMPORTS ON NATURE OF ILLIESS OF INSU	Output All CTHERT DATE Ann DD VY DODR 4 17.8 Mail DD VY DODR 5 17.9 Mail DD VY VIX AND CHARGE IN PAPER. Mail DoD Payer. DD Mail DoD Payer. Y F Mease And provinces the before (HD) DD Hell DD DD	16. DATES PATIENT UNABLE TO WO FROM DO TO	TO LIAPENT SERVICES TO SCHARGES			
	Opened Set A CONSTRUCTION And DO VY COURT TYN M DO VY Strain Council out of the strain	14. DATES PATENT UNABLE TO WO FROM DIATEST UNABLE TO WO FROM DIATEST PLAT FROM DIATEST PLAT FROM DIATEST PLAT PROM DIATEST PLAT 20. OUTSIDE LAB? NO 22. BERIMISSION ORIC GODE ORIC	TO LIAPENT SERVICES TO SCHARGES			
He GATE OF QUINTERY LUNCES AND	DATE DATE <td< td=""><td>16. DATES PATENT (INABLE TO WO FROM 16. HOSPITULATING DATES RELAT FROM 10. HOSPITULATING DATES RELAT PROM 10. HOSPITULATING DATES 10. HOSPITULATING NUMBER 22. EB55 500 500 10. HOSPITULATING NUMBER 23. PRIOR AUTHORIZATION NUMBER</td><td>TO CUMENT BENNCES</td></td<>	16. DATES PATENT (INABLE TO WO FROM 16. HOSPITULATING DATES RELAT FROM 10. HOSPITULATING DATES RELAT PROM 10. HOSPITULATING DATES 10. HOSPITULATING NUMBER 22. EB55 500 500 10. HOSPITULATING NUMBER 23. PRIOR AUTHORIZATION NUMBER	TO CUMENT BENNCES			
A Gine Co Chamery Lunds and American One Control of the Control of Control A control of the Second Control of Control	Daturc 2011 Autor 2011 Autor 2011 Autor 2011 Daturc 2012 Table 2011 Autor 2011 Do VY Daturc 2012 Table 2011 Autor 2011 Do VY Daturc 2012 Table 2011 Autor 2011 Do VY Daturc 2012 Table 2011 Do VY Do VY Daturc 2012 Table 2011 Do VY Do VY Daturc 2012 Daturc 2011 Do VY Do VY Daturc 2012 Daturc 2011 Daturc 2011 Do VY Daturc 2012 Daturc 2011 Daturc 2011 Daturc 2011 Daturc 2011 Daturc 2011 Daturc 2011 Daturc 2011 Daturc 2011 Daturc 2011 Daturc 2011 Daturc 2011	14. DATES PATENT UNABLE TO WO FROM DIATEST UNABLE TO WO FROM DIATEST PLAT FROM DIATEST PLAT FROM DIATEST PLAT PROM DIATEST PLAT 20. OUTSIDE LAB? NO 22. BERIMISSION ORIC GODE ORIC	TO LIAPENT SERVICES TO SCHARGES			
A GATE OF CHARGE GLASS BUT AN ADDRESS SUB-CHARGE GLASS BUT AND ADDRESS ALMAGE OF REFERENCE PROVIDED OF CHARGE A GOOD DIEGO OF REFERENCE PROVIDED OF CHARGE A GOOD DIEGO OF REFERENCE OF REFEREN	Daturc Data	16. Dates parter (Jwalac 10 vro 1700 Inc. 20 vro 1700 1700 Inc. 000170/JUA 1000 Dates (BLAT 1000 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 <td>TO CHARACT SERVICES</td>	TO CHARACT SERVICES			
A GATE OF CHARGE GLASS BUT AN ADDRESS SUB-CHARGE GLASS BUT AND ADDRESS ALMAGE OF REFERENCE PROVIDED OF CHARGE A GOOD DIEGO OF REFERENCE PROVIDED OF CHARGE A GOOD DIEGO OF REFERENCE OF REFEREN	Daturc Data Data Data Data Dot V Data Tris ani Data Dot Data Data<	6. DATES PATER (JUNALE TO WO FROM FROM FROM JOST TABLE TO WO FROM JOST TABLE F. JOST TABLE F. JOST TABLE JOST TABLE	TO TO CURRENT SERVICES Y			
Loss of the second	Daturc Data Data Data Data Dot V Data Tris ani Data Dot Data Data<	16. Dates parter (Jwalac 10 vro 1700 Inc. 20 vro 1700 1700 Inc. 000170/JUA 1000 Dates (BLAT 1000 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 <td>TO CHARACT SERVICES</td>	TO CHARACT SERVICES			
A GATE OF CHARGE GLASS BUT AN ADDRESS SUB-CHARGE GLASS BUT AND ADDRESS ALMAGE OF REFERENCE PROVIDED OF CHARGE A GOOD DIEGO OF REFERENCE PROVIDED OF CHARGE A GOOD DIEGO OF REFERENCE OF REFEREN	Daturc Data Data Data Dot V Data The Data Dot Dot Dot Data C Dot	16. Dates parter (Jwalac 10 vro 1700 Inc. 20 vro 1700 1700 Inc. 000170/JUA 1000 Dates (BLAT 1000 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 <td>то с с с с с с с с с с с с с с с с с с с</td>	то с с с с с с с с с с с с с с с с с с с			
A GATE OF CHARGE GLASS BUT AN ADDRESS SUB-CHARGE GLASS BUT AND ADDRESS ALMAGE OF REFERENCE PROVIDED OF CHARGE A GOOD DIEGO OF REFERENCE PROVIDED OF CHARGE A GOOD DIEGO OF REFERENCE OF REFEREN	Daturc Data Data Data Dot V Data The Data Dot Dot Dot Data C Dot	16. Dates parter (Jwalac 10 vro 1700 Inc. 20 vro 1700 1700 Inc. 000170/JUA 1000 Dates (BLAT 1000 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 <td>то с с с с с с с с с с с с с с с с с с с</td>	то с с с с с с с с с с с с с с с с с с с			
Loss of the second	Daturc Data Data Data Dot V Data The Data Dot Dot Dot Data C Dot	16. Dates parter (Jwalac 10 vro 1700 Inc. 20 vro 1700 1700 Inc. 000170/JUA 1000 Dates (BLAT 1000 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 <td>то — се и и и и и и и и и и и и и и и и и и</td>	то — се и и и и и и и и и и и и и и и и и и			
Loss of the second	Daturc Data Data Data Dot V Data The Data Dot Dot Dot Data C Dot	16. Dates parter (Jwalac 10 vro 1700 Inc. 20 vro 1700 1700 Inc. 000170/JUA 1000 Dates (BLAT 1000 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 <td>то с с с с с с с с с с с с с с с с с с с</td>	то с с с с с с с с с с с с с с с с с с с			
Loss of the second	Daturc Data Data Data Dot V Data The Data Dot Dot Dot Data C Dot	16. Dates parter (Jwalac 10 vro 1700 Inc. 20 vro 1700 1700 Inc. 000170/JUA 1000 Dates (BLAT 1000 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 <td>то с с с с с с с с с с с с с с с с с с с</td>	то с с с с с с с с с с с с с с с с с с с			
Loss of the second	Daturc Data Data Data Dot V Data The Data Dot Dot Dot Data C Dot	16. Dates parter (Jwalac 10 vro 1700 Inc. 20 vro 1700 1700 Inc. 000170/JUA 1000 Dates (BLAT 1000 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 Inc. 000170 Dates (BLAT 1000170 100 <td>то — се и и и и и и и и и и и и и и и и и и</td>	то — се и и и и и и и и и и и и и и и и и и			
A GATE OF CHARGE GLASS BUT AN ADDRESS SUB-CHARGE GLASS BUT AND ADDRESS ALMAGE OF REFERENCE PROVIDED OF CHARGE A GOOD DIEGO OF REFERENCE PROVIDED OF CHARGE A GOOD DIEGO OF REFERENCE OF REFEREN	DAMAGE 104 DALAGE 1041 Mail DD VY DAMAGE 104 TA DD DD VY DAMAGE 104 TA DD DD VY DAMAGE 104 DD DD DD DD DAMAGE 104 DD DD DD DD DAMAGE 104 DD DD DD DD DD DAMAGE 104 DD		то с с с с с с с с с с с с с с с с с с с			
As good Dicture PLANES AND Annual PLANES AN	DAVANCE AND A 201001 ANT Aut DD VY DAVANCE AND TA DD VY DAVANCE AND TA DD VY DAVANCE AND		то с с с с с с с с с с с с с с с с с с с			
As GATE OF UNITED TALKES AND	20400-0193 ACCENT ACCOUNT NO. 20400-0193 ACCOUNT NO. 20400-01		то с с с с с с с с с с с с с с с с с с с			
AL ANT OCCUPIENT LANSA AN A MARK MARK AN A MAR	20400-0193 ACCENT ACCOUNT NO. 20400-0193 ACCOUNT NO. 20400-01		то с с с с с с с с с с с с с с с с с с с			
As GATE OF UPPERTY LUNCS. NO. Non-Net Net Net Net Net Net Net Net Net Net	20400-0193 ACCENT ACCOUNT NO. 20400-0193 ACCOUNT NO. 20400-01		то с с с с с с с с с с с с с с с с с с с			

TEP 2: DBA FORM

SAMPLE DBA F	ORM			ci pi st	ard (never W ayers and pa ate patient p	VA). C tients lans a	cording to patient's Dnly commercial under 19. Out of are o.k. – you may
EALTH INSURANCE CLAIM FO				n	ed to submi	t to lo	cal payer address.
ROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (N	UCC) 02/12						PICA
MEDICARE MEDICAID TRICARE	CHAMPVA	GROUP FR	LA OTHER	1a. INSURED'S I.D. N	LMRER		(For Program in Item 1)
(Medicare#) (Medicaid#) (ID#:DoD#)	(Member ID4)	HEALTH PLAN 000					
PATIENT'S NAME (Last Name, First Name, Middle Initial)	3.1	MU DO YY	SEX	4. INSURED'S NAME	(Last Name, Firs	t Name,	Middle Initial)
PATIENT'S ADDRESS (No., Street)		M PATIENT RELATIONSHIP TO	F	7. INSURED'S ADOR	FEE Dis Frenti		
WINELL & NOVIESS (NV. SHOP)		Self Spouse Child	Other	7. INSURED S REUR	699 (NV, 9199)		
Υ.	STATE 8.1	RESERVED FOR NUCC USE		CITY			STATE
CODE TELEPHONE Brokele Area	out	as com	nlota	ly ac	tho		
administrati	on f	orm wi	th so	me a	dant	a	tions.
THEN MELHER'S FOLLY ON GROOT NOMEON				A. INSURED'S DATE	OF BRUDE		
RESERVED FOR NUCC USE		VES		h otver o verie	(Decise alord C M	1000	
		VES [PLACE (State)	b. OTHER CLAIM ID	consignated by N	000)	
ESERVED FOR NUCC USE	c.0	OTHER ACCIDENT?		c. INSURANCE PLAN	NAME OR PRO	GRAM N	CAME
		YES	NO				
NSURANCE PLAN NAME OR PROGRAM NAME	100	E. CLAIM CODES (Designate	I by NUCC)	d. IS THERE ANOTH	1		
READ BACK OF FORM BEFORE C	OMPLETING & S	IGNING THIS FORM.			1		te items 9, 9a, and 9d. SIGNATURE I authorize
READ BACK OF FORM BEFORE C PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE 1 to process this claim. I also request payment of government b	authorize the relea enefits either to m	se of any medical or other info yself or to the party who accept	mation necessary Is assignment	payment of medical services described	al benefits to the u	andersig	ned physician or supplier for
below.							
SIGNED		DATE		SIGNED			
DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY MM DO YY OLIAL	(LMP) 15. OTH QUAL	ER DATE MM DO		16. DATES PATIENT MM D	UNABLE TO WO	RK IN C	SURBENT OCCUPATION
NAME OF REFERRING PROVIDER OR OTHER SOURCE	17a.	1			N DATES RELAT		CURRENT SERVICES
	175. N	4		FROM	0 Yr	TO	
ADDITIONAL CLAIM INFORMATION (Designated by NUCC		19		20. OUTSIDE LAB?		S C	HARGES
A good place for processing notes to pa biagnosis OR NATURE OF ILLNESS OR INJURY. Read		-		YES	NO		
Z 23		te below (24E) ICD Ind.		22. RESUBMISSION CODE	ORIO	SINAL P	IEF. NO.
	a.L	D.		23. PRIOR AUTHOR	ZATION NUMBE	R	
J. J.L.,	K.L	L					
A DATE(S) OF SERVICE B. C. From To PLACEOF PLACEOF	D. PROCEDUR (Explain U	ES, SERVICES, OR SUPPLI rusual Circumstances)	DIAGNOSIS	F.	G. H. DAYS EPSOT OR Family	L 10.	J. RENDERING
I DO YY MM DD YY SERVICE EMG	CPT.HCPCS	MODIFIER	POINTER	\$ CHARGES	UNTS Per	CALME.	PROVIDER ID. #
C with DOS	See grid	No modifer	Tie to 21	See grid		NPI	Provider numbers
						NPI	Provider numbers
		24d		24f		NPI	Provide rankers
							,
						NPI	Provider numbers
		1 1 1 1				NPI	Provider numbers
	-					7821	r rovider numbers
							Provider numbers
	PATIENT'S ACCO		ASSIGNMENT?	28. TOTAL CHARGE	No ch	UNT PA	ID 30. Revel for NUCC L
7-2251833 25 V	CEDUCE EACH C	YES	NO	\$ 33. BILLING PROVID	patien	it 👘	
INCLUDING DEGREES OR CREDENTIALS	yers compa	re this to 24B		Phone numb	er is alwavs		ider's billing office.
	ace of service	n codo		PO Box 9400	2		
apply to this bill and are made a part thereot.) pla	ice of servic	e coue		Seattle, WA	98124-9402		22

ELECTRONIC

File forms electronically **OR** by mail.

Crossover Guide for Dosage-Based Assessment Electronic Submission



STEP 1

Complete the DBA Form electronically (837 Professional)

The form includes:

- 1. Billing Provider Federal Tax ID Number
- 2. Billing Provider Information
- 3. Patient Account Number, Claim Notes and Provider Signature
- 4. Rendering Provider Name
- 5. Service Facility & Location NPI
- 6. Service Line and Date of Service
- 7. Procedures, Services and Supplies
- 8. Line Item Charge (\$) Amount
- 9. Drug Identification

STEP 2

Submit electronically to payer

Submit the DBA Form to the payer (health plan, insurance company, or third-party administrator) via your company clearinghouse – NOT to WVA.

BILLING TIPS

★ Do NOT submit to WVA.

★ First time electronic filers:

The first time you use the electronic DBA process, please notify your claim clearinghouse that you intend to submit the electronic form using the DBA process with WVA's name. Tax ID and NPI.

* Important Numbers

WVA Tax Identification Number (TIN): 27-2251833

WVA National Provider Identifier (NPI): 1699092718

WVA Billing Taxonomy Number: 251K00000x

DBA FORM (837 Professional)

X12N 837, Version 5010A1 Claim - Field Description	Loop	Segment/ Element	Qualifier	Qualifier Description	Data for WVA DBA Process	CMS-1500 Bo Crosswalk
Billing Provider						
Federal Tax ID Number (TIN)	2010AA	REF01	E1	For EIN		None
TIN	2010AA	REF02			27-2251833	Box 25
Billing Provider Information	2010AA	NM101	85	Billing Provider		None
Billing Provider Entity Type	2010AA	NM102	2	Organization		None
Billing Organizational Name	2010AA	NM103			Washington Vaccine Association	Box 33
Identification Code Type	2010AA	NM108	XX	NPI		None
National Provider Identifier (NPI)	2010AA	NM109			1699092718	Box 33a
Billing Provider Taxonomy	2000A	PRV01	BI	Billing		None
Identification Qualifier Code	2000A	PRV02	PXC	Taxonomy		None
Identification Code Type	2000A	PRV03			251K00000X	Box 33b
Billing Provider Address	2010AA	N3			Leave Blank	None
Billing Provider Address - Line 1	2010AA	N301			Marketplace Tower PH-A	Box 33
Billing Provider Address - Line 2	2010AA	N302			2025 First Ave	Box 33
Billing Provider City	2010AA	N401			Seattle	Box 33
Billing Provider State	2010AA	N402			WA	Box 33
Billing Provider ZIP Code	2010AA	N402			981213125	Box 33
				Information Contact	361213123	
Billing Provider Contact	2000A	PER01	IC	Information Contact		None
Identification Code Type	2000A	PER03	TE	Telephone Number	Lies the Service Provider's Piller	None
Rilling Provider Telephone Number	2000A	PER04			Use the Service Provider's Billing Office/Contact Telephone Number	Box 33
Billing Provider Telephone Number	2000A	PER04			Chicercontact relephone Number	B0X 33
Dev To Deviden Mar	0040	hinder	07	Dev To Devil	Markinster March 1	News
Pay-To Provider Name	2010AB	NM101	87	Pay-To Provider	Washington Vaccine Association	None
Pay-To Entity Type	2010AB	NM102	2	Organization		None
Pay-To Address - Line 1	2010AB	N301			PO Box 94002	None
Pay-To City	2010AB	N401			Seattle	None
Pay-To State	2010AB	N402			WA	None
Pay-To ZIP Code	2010AB	N403			981249402	None
Patient Account Number	2300	CLM01				Box 26
Total Charge	2300	CLM02			Total Charge Amount	Box 28
	2300	CLM05-1	11	Office		Box 24B
Provider Signature Indicator	2300	CLM06	Y	Yes		Box 31
Note	2300	NTE	-			None
				Indicates additional		
Note Reference Code	2300	NTE01	ADD	information for claim		Box 19
Note Text	2300	NTE02			claim	Box 19
Rendering Provider Name	2310B	NM1				None
Identification Code Type	2310B	NM101	82	Rendering Provider		None
Identification Code Type	2310B	NM102	1	Individual		None
Identification Code Type	2310B	NM108	xx	NPI		None
Identification Code Type	2310B	NM109	100		Use Rendering Provider's NPI #	Box 24J
	20100				Cool to horing i to hori o hiring	SOA ETO
Service Facility Location Information	2310C					None
Service Facility Identifier	2310C	NM101	77	Service Location		None
Service Facility Identifier	23100	NWI UI	FA		Facility	None
Convice Facility Type	22100	NIMIOO		Facility	r oonty	
Service Facility Type	2310C	NM102	2	Non-Person Entity		None Day 20
Service Facility Name	2310C	NM103				Box 32
		0.004	1.00			
Service Line, Service Date(s)	2400	DTP01	472	Date of Service		None
Service From - To Dates	2400	DTP02	RD8	Range of Dates of Service		None
Format as: CCYYMMDD-CCYYMMDD	2400	DTP03				Box 24A
Procedures, Services, Supplies	2400	SV1				None
Product/Service ID	2400	SV101-1	HC	Standard CPT Code		None
Procedure-CPT/HCPCS Code	2400	SV101-2				Box 24D
Line Item \$ Charge Amount	2400	SV102				Box 24F
Drug Identification	2410	LIN				None
				Must be N4 (No		Box 24 Shaded
Product or Service Identification Code	2410	LIN02	N4	description given)		area for servic
						Box 24 Shadeo
National Drug Code NDC #	2410	LIN03			11-digit NDC #	area for servic
Drug Quantity	2410	CTP				None
					Unit price, based upon the unit of	Box 24 Shade
Drug Unit Price	2410	CTP03			measure as defined by the NDC.	area for servic
					the unit of measure as defined by	Box 24 Shade
National Drug Unit Count/Quantity	2410	CTP04			the NDC.	area for servic
					measurement code (UN, ML, F2 or GR)	Box 24 Shade
Unit or Basis for Measurement Code	2410	CTP05-1				area for servic

QUESTIONS?

We are here to help! You can find answers to many billing questions on the "FAQs" page at **www.wavaccine.org.**

3

Takeaways for Providers and Payers

When providers and payers participate in the WVA dosage-based assessment (DBA) process, it allows the WVA to collect the necessary assessments from insurance carriers and third-party administrators that in turn allows Washington to continue to provide vaccines to protect all children in our state.

TAKEAWAYS FOR PROVIDERS

- The WVA's Vaccine Assessment Grid is posted on its website and contains the most up-to-date information on vaccine material CPT and NDC codes and charges to use on the DBA submission – <u>see https://wavaccine.org/assessment-grid/.</u>
- Providers only need to submit DBAs for CVP vaccine material for privately-insured patients under the age of 19.
- Providers should not submit DBAs on behalf of patients with other types of insurance such as Apple Health (Medicaid) or managed-Medicaid products.
- Use the prior two pages as reference for filing by mail or electronically.
- Providers should consult the WA Department of Health's (DOH) *Eligibility for Publicly Funded Vaccines A Guide for Providers* to determine if a DBA for the WVA is required.

The DOH can assist you with questions about:

- Provider enrollment in the Vaccine for Children (VFC) program and program requirements, including site visits.
- Vaccine ordering and the State's Immunization Information System (IIS).
- Center for Disease Control (CDC) requirements and education on storage, handling, and waste.
- Non-commercially insured, traditional Medicaid, managed Medicaid (Apple Health), and uninsured patients.
- Questions regarding brand choice.

VACCINE CLAIM/ASSESSMENT FOLLOW UP

If the administration and/or DBA is denied for incorrect provider demographic or patient eligibility information, lacking a National Drug Code (NDC), or other reason, the provider must re-file both the corrected administrative and vaccine material DBA forms to the carrier or TPA. The WVA relies on provider offices to pursue payment of the DBA, or vaccine portion of the claim, to the full extent they pursue payment of the administration portion of the claim. The WVA does not submit claims directly to carriers and TPAs, and relies on correct DBA processing in order to maintain program funding.

TAKEAWAYS FOR PAYERS

Participation and Regulatory Requirements

- There are no provider network participation requirements for the WVA to be reimbursed by a carrier or Third-Party Administrator (TPA) who receives a DBA from a provider.
- TPAs are required by RCW 70.290.075 to register on the <u>WVA website</u> (<u>https://wavaccine.org/registration-requirements/</u>).
- Carriers and TPAs are required to ensure their adjudication systems pay according to the WVA Vaccine Assessment Grid price. The price is set by CPT and NDC code annually on July 1st see <u>https://wavaccine.org/assessment-grid/.</u>

Patient Responsibility

• There are no contractual adjustments or patient responsibility associated with DBA's.

DBA Adherence

- The WVA does not submit DBAs itself and receives remits from carriers and TPAs only. DBAs are only submitted by providers on behalf of the WVA to the payers.
- If a provider cannot separate the provider's administrative fee from the vaccine material fee (DBA), the payer must produce a settlement report to the WVA until the provider can bill a separate DBA.

Other

- Carriers and TPAs can reduce their administrative expenses by submitting electronic remittance advices (ERAs) and electronic fund transfers (EFTs) to the WVA. Payment may also be made via check, but not by VCP. To sign up for electronic remittance, please <u>email</u> <u>info@wavaccine.org</u> with your request and contact information so we can follow up with you.
- Each year payers and TPAs are provided a Statutory Assessment letter which contains an estimate of future-year payments to the WVA for informational/budgeting purposes.
- The WVA is a non-profit entity that does not require a 1099. The 1099 results in administrative expense for the carrier/TPA and the WVA. A WVA W9 may be downloaded from our website if required see https://wavaccine.org/other-resources-and-links/.

Overpayments, Refunds and Takebacks

- If payers have made payments to providers instead of the WVA for vaccine material, payers are responsible to reverse the payment and re-process for remittance to the WVA.
- The WVA asks payers to seek refunds with DBA-specific information (claim number, DOS, patient ID, charges, paid amounts) in order for a refund check to be mailed to payers.
- The WVA does not accept takebacks, vouchers, or off-sets from payers when claims are reprocessed by payers seeking reimbursement for overpaid DBAs.
- If a payer is planning to reprocess DBAs in bulk, we would ask they reach out to us to make arrangements (e.g., a lump payment with claim-specific notation) in order to reduce manual refund check processing costs.

4

Stay connected.



<u>www.wavaccine.org</u> <u>info@wavaccine.org</u> Ph 888-928-2224 Fax 888-928-2242

Mailing Address: PO Box 94002 Seattle, WA 98124-9402



www.doh.wa.gov WAChildhoodVaccines@doh.wa.gov 360-236-3595 or 1-866-397-0337 (toll free)

Mailing Address:

Washington State Childhood Vaccine Program Office of Immunization and Child Profile Washington State Department of Health P.O. Box 47843 Olympia, Washington 98504-7843